Loading…
Acadia Healthcare Company, Inc.
🏹 Trader: 📈 Stage 2 View all →
📈 Stage 2 detected Find the fundamental catalyst → → run Growth Triggers in Ask AI
$2.5B
Market Cap
14.3
P/E
27.20
PEG
-19.4%
ROCE
-41.0%
ROE
1.21
D/E
-28.2%
OPM
-19.3%
% from 52W High
81
α RS
🔍 ACHC is showing a sector-leadership setup because Sector RRG has Health Care in the Leading quadrant with the trail still strengthening, RS Rating is 81, and an ECS of 53.4 last quarter. Net: Broad signal stack, not a recommendation. ? RRG RS Rating ECS
Sources
Health Care in Leading quadrant · RS Rating 81 · ECS 53.4
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for ACHC including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding ACHC
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 536.5K $12.5M 0.02% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific ~ Volatile 4 quarters Full tone analysis in Intelligence →
📊 MIXED Acadia Healthcare: Q1 revenue $828.8M, Adjusted EBITDA $144.2M, 275 facilities serving 84K+ patients daily.
Revenue & Profitability
Revenue for Q1 2026 was $828.8 million, a 7.6% increase year-over-year. Same-facility revenue grew 7.3%, driven by 5.6% higher revenue per patient day and 1.6% more patient days. Adjusted EBITDA was $144.2 million (7.5% growth), exceeding the high end of guidance by $7.2 million. Adjusted EPS guidance for full year was raised to $1.35-$1.60 from $1.30-$1.55. Free cash flow was negative $15 million in Q1, improving $148 million from Q1 2025.
Outlook
Management sees continued strong demand for behavioral health services, citing escalating unmet need. Headwinds include severe weather impacts ($3.7 million in Q1), specialty headwinds in Pennsylvania from New York's decision to not place residents, and rising bad debts and denials. Supplemental payment programs under regulatory review could add at least $22 million in incremental EBITDA, with potential upside from Florida. The company expects its net leverage to temporarily increase to 4.4-4.5x in Q2 before returning to 3.9-4.2x by year-end.
Growth Drivers
Key growth drivers include acute inpatient psychiatric facilities (14% revenue growth in Q1), adding 400-600 beds in 2026 (82 added in Q1), and ramping facilities opened since 2023, which are expected to deliver $200 million of Adjusted EBITDA growth relative to 2025. New JV facilities opened in Q1 (Tufts Medicine in Boston) and expected in Q2 (Premier Health, Orlando Health, Methodist Jennie Edmundson). The company also focuses on improving referral networks and marketing to drive admissions.
Balance Sheet & CapEx
Capital expenditure guidance for 2026 is $255-$280 million, over $300 million lower than 2025. First half CapEx is higher due to new JV facility openings. In Q1, the company added 82 beds, closed 251 beds (mainly leased facilities in Pennsylvania and other announced closures). Investments include technology, data tools, and early-stage AI for revenue cycle management to improve operational efficiency.
Margins
Adjusted EBITDA margin for Q1 was approximately 17.4% ($144.2M on $828.8M revenue). Performance exceeded guidance due to better-than-planned cost efficiencies at corporate and facility levels, as well as outperformance from newer facilities. Startup facility losses were $12 million in Q1, better than the $14 million forecast, and are expected to peak at $15 million in Q2 before improving in the second half. The company is focusing on aligning staffing resources, reducing premium labor, and improving workforce planning to drive margin improvement.
Key Risks
Key risks highlighted include rising bad debts and denials across payers (broader-based, not one specific type), specialty headwinds from New York's decision to stop referrals to Pennsylvania facilities, adverse weather impacts, and potential delays in supplemental payment program approvals. The company also faces temporary higher leverage in Q2 2026 due to rolling EBITDA calculation and execution risk in ramping new facilities. No other major risks were discussed.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-29
Second quarter results met or exceeded guidance, with strong free cash flow, disciplined capital deployment, and accelerated ramp-up at new facilities. Revenue was flat year-over-year but grew 2.8% after normalizing for supplemental payments. Leadership changes and operational focus are driving improved execution.
Q1 2026 Q1 2026 2026-04-30
Revenue and Adjusted EBITDA exceeded guidance in Q1 2026, driven by strong acute and RTC performance. Full-year Adjusted EBITDA and EPS guidance were raised, while operational improvements and leadership changes support continued growth.
Q4 2025 Q4 2025 2026-02-25
Q4 and full-year 2025 saw solid revenue and EBITDA growth, with expansion through joint ventures and disciplined capital allocation. 2026 guidance anticipates modest volume growth, lower CapEx, and a focus on operational excellence amid regulatory and payer headwinds, especially from New York Medicaid changes.
Q3 2025 Q3 2025 2025-11-06
Q3 2025 revenue grew 4.4% year-over-year, but Adjusted EBITDA declined due to Medicaid volume softness and higher expenses. 2025 guidance was lowered, CapEx is being reduced, and five underperforming facilities were closed to optimize the portfolio.
Q2 2025 Q2 2025 2025-08-06
Q2 2025 revenue rose 9.2% to $869.2M, with Adjusted EBITDA up 7.5% year-over-year. Medicaid volumes were pressured, but commercial and Medicare volumes grew. Guidance was updated for lower volume growth and higher startup costs, offset by increased supplemental payments.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.